NCT06845254Not yet recruitingPhase 3
Clinical Study on the Intervention of Xuesaitong Soft Capsules in Post-Intervention Patients with Acute Coronary Syndrome and Clinical Research Protocol
Clinical Study and Molecular Mechanism of Xuesaitong Soft Capsule in the Treatment of Acute Coronary Syndrome After Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 25 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To assess the effects of Xuesaitong soft capsules on platelet function, clinical efficacy, prognosis, and safety in the treatment of acute coronary syndrome, 400 patients with acute coronary syndrome who underwent PCI were treated with Xuesaitong soft capsules (mainly containing ginsenosides) for 12 weeks.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 16 Feb 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 1 Oct 2025
- Lead sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
- Diseases
- Coronary artery disease
- NCT number
- NCT06845254
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 400
- From 1 Mar 2025 to the primary completion date, 1 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled hypertension after medication (systolic BP \>180mmHg or diastolic BP \> 110mmHg).
- Increased bleeding risk: history of hemorrhagic stroke; intracranial aneurysm; major trauma or surgery within the past month (including Exclusion Criteria bypass surgery); active bleeding disorders.
- History of gastrointestinal ulcers or significant gastrointestinal bleeding.
- History of malignant arrhythmias within the past year (arrhythmias affecting hemodynamics requiring medication or electrical cardioversion, or requiring CPR), congenital heart disease, or malignant tumors.
- History of alcohol abuse (≥28 standard units/week for males, ≥21 standard units/week for females) or frequent alcohol consumption in the past 6 months (≥14 standard units/week).
- History of drug abuse or dependence within the past year. Participation in other clinical trials and taking trial drugs within the past 3 months.
- Allergy or intolerance to aspirin or P2Y12 receptor inhibitors.
- Allergy to any components of the trial drug.
- Other conditions deemed inappropriate for participation by the nvestigator
Lab values
- Severe organic heart disease, such as LVEF \< 35% or NYHA/Killip heart function grade IV.
- Severe liver or kidney dysfunction: ALT or AST ≥ 3×ULN, TBIL≥ 2×ULN, or creatinine clearance \< 30ml/min.
Other
- Pregnant or lactating women.
- Recent blood donation or significant blood loss within the past 3 months (≥400ml).
Who the study is looking for
- Patients diagnosed with acute ST-segment elevation myocardial infarction, acute non-ST-segment elevation myocardial infarction, or unstable angina according to Western medical standards. Inclusion Criteria.
- Within 4 weeks post-PCI.
- Aged between 18 and 80 years, both male and female.
- Voluntarily participating in the clinical trial, having signed the informed consent form.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xiyuan Hospital, China Academy of Chinese Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.